AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8054125 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation (6 hours of bedrest post sheath removal)
Number of subjects: 85
Study 8054125 — intervention group
Group type: COMPARATOR
Intervention: Standard care (8 hours of bedrest post sheath removal)
Number of subjects: 85
Study 2903219 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexposure condition (30 bursts of white noise while monitoring nonsense syllables)
Number of subjects: 106
Study 2903219 — intervention group
Group type: COMPARATOR
Intervention: Non-preexposure condition (listening to nonsense syllables without white noise)
Number of subjects: 106
Study 2903219 — intervention group
Group type: EXPERIMENTAL
Intervention: Retesting after 6 to 7 weeks for both acute and chronic patients
Number of subjects: 106
Study 1586711 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-3/rhGM-CSF
Number of subjects: 15
Study 1586711 — intervention group
Group type: COMPARATOR
Intervention: rhIL-3
Number of subjects: 15
Study 1586711 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rhIL-3
Number of subjects: 15
Study 363047 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin administered intravenously
Number of subjects: 0
Study 363047 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin administered intramuscularly
Number of subjects: 0
Study 363047 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin (general use)
Number of subjects: 0
Study 31378010 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial emotional cue of anger
Number of subjects: 251
Study 31378010 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial emotional cue of sadness
Number of subjects: 251
Study 31378010 — intervention group
Group type: COMPARATOR
Intervention: Facial emotional cue of neutral expression
Number of subjects: 251
Study 31378010 — intervention group
Group type: COMPARATOR
Intervention: Absence of facial expression
Number of subjects: 251
Study 31378010 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall aggression levels across conditions for men
Number of subjects: 251
Study 31378010 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall aggression levels across conditions for women
Number of subjects: 251
Study 31378010 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental motives
Number of subjects: 251
Study 28319997 — intervention group
Group type: EXPERIMENTAL
Intervention: Single glucocorticoid intradiscal injection (25 mg prednisolone acetate)
Number of subjects: 135
Study 28319997 — intervention group
Group type: COMPARATOR
Intervention: Discography alone (control group)
Number of subjects: 135
Study 26510577 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation (intensive visits every 3-4 weeks in year 1, 6-12 weeks in year 2)
Number of subjects: 5292
Study 26510577 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation (sustainability visits every 6-12 weeks in year 2)
Number of subjects: 5292
Study 23452107 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smoking (more than one pack of cigarettes per day)
Number of subjects: 763
Study 23452107 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 763
Study 23452107 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 763
Study 23452107 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking the first cigarette of the day within 30 min of waking
Number of subjects: 763
Study 23452107 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking initiation at earlier age
Number of subjects: 763
Study 23452107 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher temptation to smoke
Number of subjects: 763
Study 23452107 — intervention group
Group type: EXPERIMENTAL
Intervention: Household smoking or living alone
Number of subjects: 763
Study 23452107 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to chemicals at work
Number of subjects: 763
Study 21481514 — intervention group
Group type: EXPERIMENTAL
Intervention: ESS-EMNCH training
Number of subjects: 36
Study 21481514 — intervention group
Group type: COMPARATOR
Intervention: Control (untrained)
Number of subjects: 36
Study 19453643 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart transplant recipients
Number of subjects: 69
Study 19453643 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplant recipients
Number of subjects: 69
Study 17803164 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 42
Study 17803164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 15067204 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg per os)
Number of subjects: 11
Study 15067204 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) (40 mg per os)
Number of subjects: 11
Study 15067204 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) (40 mg per os) during hyperprolactinemia
Number of subjects: 11
Study 15067204 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (HC) alone
Number of subjects: 11
Study 15067204 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) during hyperprolactinemia
Number of subjects: 11
Study 11440295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhalers, duration of smoking abstinence categorized as recidivists (0 days smoke free), short-term abstainers (1-7 days smoke free), or longer-term abstainers (>7 days smoke free)
Number of subjects: 0
Study 11440295 — intervention group
Group type: COMPARATOR
Intervention: Recidivists (0 days smoke free)
Number of subjects: 0
Study 11440295 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer-term abstainers (>7 days smoke free)
Number of subjects: 0
Study 9663811 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor preparations
Number of subjects: 132
Study 7820329 — intervention group
Group type: EXPERIMENTAL
Intervention: E3810 single oral doses (1, 3, 10, 20, 40 and 80 mg) in fasting conditions
Number of subjects: 0
Study 7820329 — intervention group
Group type: EXPERIMENTAL
Intervention: E3810 single oral dose (20 mg) after a meal
Number of subjects: 0
Study 7820329 — intervention group
Group type: EXPERIMENTAL
Intervention: E3810 repeated oral doses (20 and 40 mg) once daily for 7 days
Number of subjects: 0
Study 3138444 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-in-1 admixture TPN
Number of subjects: 200
Study 3138444 — intervention group
Group type: COMPARATOR
Intervention: Conventional TPN
Number of subjects: 200
Study 3138444 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 200
Study 28780685 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based health education program
Number of subjects: 55
Study 28780685 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 55
Study 27957596 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable inflatable InSpace™ system
Number of subjects: 24
Study 26100824 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg single dose)
Number of subjects: 30
Study 26100824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24229676 — intervention group
Group type: EXPERIMENTAL
Intervention: T80/H25
Number of subjects: 888
Study 24229676 — intervention group
Group type: COMPARATOR
Intervention: T80
Number of subjects: 888
Study 21724872 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TJ‐100) 5-g administration
Number of subjects: 0
Study 21724872 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TJ‐100) 2.5 to 10 g/day
Number of subjects: 0
Study 18805510 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding intervention
Number of subjects: 0
Study 18805510 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17165237 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 100
Study 17165237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17165237 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 100
Study 15274666 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg daily and tinidazole 500 mg two tablets daily with lansoprazole 30 mg daily for 6 days (ATL-group)
Number of subjects: 131
Study 15274666 — intervention group
Group type: COMPARATOR
Intervention: Placebo with tinidazole and azithromycin (ATP-group)
Number of subjects: 131
Study 11071674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.3 mg)
Number of subjects: 30
Study 11071674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.14 mg/kg)
Number of subjects: 30
Study 11071674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous and intrathecal)
Number of subjects: 30
Study 8871173 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg)
Number of subjects: 15
Study 8871173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8871173 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg) in supplementary experiments
Number of subjects: 15
Study 1386245 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 8 mg of ondansetron followed by a 24 h infusion of 1 mg h‐1 (group 1)
Number of subjects: 535
Study 1386245 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 32 mg of ondansetron (group II)
Number of subjects: 535
Study 1386245 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 8 mg of ondansetron (group III)
Number of subjects: 535
Study 1386245 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ondansetron efficacy based on gender
Number of subjects: 535
Study 6370981 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 61
Study 6370981 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 61
Study 6370981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 29314146 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) 400 mg + Daclatasvir (DCV) 60 mg daily + weight-based Ribavirin (RBV) for 12 weeks (or 24 weeks if RBV contraindicated)
Number of subjects: 551
Study 29314146 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Daclatasvir (DCV) + Ribavirin (RBV)
Number of subjects: 551
Study 29121974 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline added to treatment as usual (TAU)
Number of subjects: 320
Study 29121974 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids added to treatment as usual (TAU)
Number of subjects: 320
Study 29121974 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline and/or omega-3 fatty acids added to treatment as usual (TAU)
Number of subjects: 320
Study 29121974 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 320
Study 26414968 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25-50 mg)
Number of subjects: 335
Study 26414968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 26414968 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 335
Study 26414968 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 335
Study 24067210 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercise combined with encouragement
Number of subjects: 120
Study 24067210 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 120
Study 20864558 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate packing (0.79 ± 0.40 liters)
Number of subjects: 14
Study 20864558 — intervention group
Group type: COMPARATOR
Intervention: No packing (control)
Number of subjects: 14
Study 18174758 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention for older smokers (62 and older)
Number of subjects: 277
Study 18174758 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation intervention for younger smokers (under 62)
Number of subjects: 277
Study 18174758 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis of smoking cessation rates
Number of subjects: 277
Study 16808827 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Doppler Imaging (PDI) protocol
Number of subjects: 76
Study 16808827 — intervention group
Group type: COMPARATOR
Intervention: Continuous wave (cw) Doppler protocol
Number of subjects: 76
Study 12496541 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal laparoscopic repair
Number of subjects: 994
Study 12496541 — intervention group
Group type: COMPARATOR
Intervention: Conventional anterior hernia repair
Number of subjects: 994
Study 10404850 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release ranolazine (various dosing regimens)
Number of subjects: 312
Study 10404850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 7562112 — intervention group
Group type: EXPERIMENTAL
Intervention: HMF (undigested high molecular fraction of soybean protein)
Number of subjects: 0
Study 7562112 — intervention group
Group type: COMPARATOR
Intervention: Casein
Number of subjects: 0
Study 2185298 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily paracentesis (3‐4 litre) and intravenous albumin infusion
Number of subjects: 40
Study 2185298 — intervention group
Group type: COMPARATOR
Intervention: Ascites recirculation (Rhodiascit apparatus)
Number of subjects: 40
Study 2185298 — intervention group
Group type: COMPARATOR
Intervention: Ascites recirculation
Number of subjects: 40
Study 2185298 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily paracentesis
Number of subjects: 40
Study 2185298 — intervention group
Group type: COMPARATOR
Intervention: Ascites recirculation and daily paracentesis
Number of subjects: 40
Study 7387803 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium chloride (10 ml of a 10% solution, containing elemental calcium 27 mg ml‐1)
Number of subjects: 10
Study 7387803 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluceptate (20 ml, containing elemental calcium 18 mg ml‐1)
Number of subjects: 10
Study 7387803 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium chloride
Number of subjects: 10
Study 7387803 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluceptate
Number of subjects: 10
Study 30834520 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent exposure to maternal socioeconomic and psychosocial indicators of adversity
Number of subjects: 319
Study 30834520 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal exposure to maternal stress symptoms
Number of subjects: 319
Study 30834520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative adversity count
Number of subjects: 319
Study 28061830 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric intervention involving systematic preoperative geriatric assessment and adjusted nutritional support according to guidelines.
Number of subjects: 0
Study 28061830 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 0
Study 26594847 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure Freedom (SF) group
Number of subjects: 73
Study 26594847 — intervention group
Group type: COMPARATOR
Intervention: Not Seizure-Free (NSF) group
Number of subjects: 73
Study 26594847 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study 24498939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) delivered by respiratory nurses
Number of subjects: 0
Study 24498939 — intervention group
Group type: COMPARATOR
Intervention: Self-help leaflets
Number of subjects: 0
Study 22014222 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based multimedia program
Number of subjects: 164
Study 22014222 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 164
Study 19408480 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allograft (ADMA)
Number of subjects: 32
Study 19408480 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 32
Study 17519560 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Ectoin
Number of subjects: 104
Study 17519560 — intervention group
Group type: COMPARATOR
Intervention: Vehicle emulsion
Number of subjects: 104
Study 17519560 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 104
Study 15365226 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 52
Study 15365226 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 52
Study 11463510 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (2000 mg/day)
Number of subjects: 11
Study 11463510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9711471 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 1.5 mg
Number of subjects: 16
Study 9711471 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg
Number of subjects: 16
Study 9711471 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 16
Study 9711471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9075195 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 172
Study 2036817 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (F)
Number of subjects: 13
Study 2036817 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (S)
Number of subjects: 13
Study 6938259 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtration leukapheresis
Number of subjects: 48
Study 6938259 — intervention group
Group type: COMPARATOR
Intervention: Gravity leukapheresis
Number of subjects: 48
Study 31852411 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured semi-interactive stroke prevention package (includes a stroke prevention workbook, regular educational short messages, and videos)
Number of subjects: 5830
Study 31852411 — intervention group
Group type: COMPARATOR
Intervention: Standard of care management
Number of subjects: 5830
Study 30734359 — intervention group
Group type: EXPERIMENTAL
Intervention: Case vignettes for oral healthcare management
Number of subjects: 1244
Study 30734359 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice or evidence-based recommendations
Number of subjects: 1244
Study 30734359 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in recognizing symptoms
Number of subjects: 1244
Study 29072020 — intervention group
Group type: EXPERIMENTAL
Intervention: Xingnao Kaiqiao needling stimulation
Number of subjects: 140
Study 29072020 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 140
Study 26679702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation, 3g/d of EPA and DHA for 12 weeks
Number of subjects: 24
Study 26679702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL, olive oil) for 12 weeks
Number of subjects: 24
Study 23926585 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic toothbrush (Philips Sonicare FlexCare® toothbrush)
Number of subjects: 83
Study 23926585 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (Oral‐B P40®)
Number of subjects: 83
Study 22002187 — intervention group
Group type: EXPERIMENTAL
Intervention: Mckenzie technique
Number of subjects: 18
Study 18541517 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia-targeted therapeutics (e.g., tirapazamine, AQ4N)
Number of subjects: 0
Study 18541517 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapeutic agents
Number of subjects: 0
Study 17162245 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 12-15 mg.kg-1.day-1 with vitamin E 400 IU twice a day (UDCA/Vit E)
Number of subjects: 48
Study 17162245 — intervention group
Group type: COMPARATOR
Intervention: UDCA with placebo (UDCA/P)
Number of subjects: 48
Study 17162245 — intervention group
Group type: COMPARATOR
Intervention: Placebo/placebo (P/P)
Number of subjects: 48
Study 17162245 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA/Vit E
Number of subjects: 48
Study 12662277 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-WBC-reduced RBC transfusion
Number of subjects: 523
Study 12662277 — intervention group
Group type: COMPARATOR
Intervention: WBC-reduced RBC transfusion
Number of subjects: 523
Study 10892946 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted blood cardioplegia (LDBCP)
Number of subjects: 50
Study 10892946 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia (BCP)
Number of subjects: 50
Study 8725891 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) before radical prostatectomy
Number of subjects: 0
Study 1920343 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 0
Study 1920343 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg
Number of subjects: 0
Study 6226187 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 0
Study 6226187 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30528725 — intervention group
Group type: EXPERIMENTAL
Intervention: .5% bupivacaine
Number of subjects: 41
Study 30528725 — intervention group
Group type: COMPARATOR
Intervention: .9% NaCl (control)
Number of subjects: 41
Study 30528725 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 41
Study 27844224 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive medial maxillectomy approach through the lacrimal recess
Number of subjects: 125
Study 27844224 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow lacrimal recess (less than 4 mm)
Number of subjects: 125
Study 27844224 — intervention group
Group type: EXPERIMENTAL
Intervention: Missing lacrimal recess
Number of subjects: 125
Study 27844224 — intervention group
Group type: COMPARATOR
Intervention: Narrow lacrimal recess
Number of subjects: 125
Study 26958746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure-lowering therapy (target systolic blood pressure, < 140 mm Hg within 1 hr)
Number of subjects: 3243
Study 26958746 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure-lowering therapy (target systolic blood pressure, < 180 mm Hg)
Number of subjects: 3243